US20040057907A1 - Dri-nasal sprays - Google Patents

Dri-nasal sprays Download PDF

Info

Publication number
US20040057907A1
US20040057907A1 US10/406,869 US40686903A US2004057907A1 US 20040057907 A1 US20040057907 A1 US 20040057907A1 US 40686903 A US40686903 A US 40686903A US 2004057907 A1 US2004057907 A1 US 2004057907A1
Authority
US
United States
Prior art keywords
composition
bio
active material
glycol
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/406,869
Inventor
Leonard Mackles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/406,869 priority Critical patent/US20040057907A1/en
Priority to US10/526,386 priority patent/US7332528B2/en
Priority to PCT/US2003/028272 priority patent/WO2004026362A2/en
Priority to CA002499900A priority patent/CA2499900A1/en
Priority to AU2003272306A priority patent/AU2003272306A1/en
Publication of US20040057907A1 publication Critical patent/US20040057907A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Definitions

  • decongestants are commercially available and are used to give various lengths of relief from 4 hours up to 12 hours. All of these decongestants are water soluble and are delivered in aqueous spray Systems.
  • the decongestant solutions are delivered by spray from either a flexible plastic container that produces a mist when squeezed or by a hand operated mechanical pump.
  • the mucous layer lining the epithelium represents a barrier to drug absorption along with mucociliary clearance mechanisms of the nose leads to short residence time of aqueous systems at the site of absorption which limits the systemic availability of the drug.
  • the invention is directed to compositions of incorporating an effective dosage of decongestant or other drug from a safe, non-aqueous, non-irritating, tastless and odorless liquid carrier system that delivers an extremely fine, non-dripping, warm, pleasant spray to the nasal cavity from either a squeeze bottle or pump spray system.
  • a non-aqueous liquid spray composition for a bioactive material comprising a pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble, a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier, a pharmacologically acceptable water soluble glycol soluble in said ester, a pharmacologically acceptable water soluble bio-active material soluble in said glycol but directly insoluble, that is to say cannot be directly dissolved in in said carrier.
  • the spray compositions of the present invention are produced by the sequential steps of dissolving the bio-active material in a glycol, dissolving the resultant solution in a water insoluble ester of a water soluble acid and dissolving said further resultant solution in a suitable carrier as discussed above.
  • the spray compositions of the present invention containing the appropriate bio-active material may be administered to a subject in need of same by spraying a pharmacologically effective amount of such a composition into the nasal cavity of said subject.
  • This may be done using any spray method, such as using a pump spray device or a squeeze bottle spray, the latter being inexpensive and especially suitable.
  • the system of the present invention possesses several advantages over the aqueous nasal administration systems heretofore available. It provides a fine, warm, dripless, non-irritating spray, which, depending on the drug used, gives 4-12 hour decongestant relief. Because the system is non-aqueous, no preservatives are needed and the system will resist recontamination.
  • the system is anhydrous, it will wet out and cling to the mucous membrane of the nasal passages. Being water resistant, it will resist removal by the mucocillary clearance mechanism; thereby allowing more contact time at the site.
  • the drugs will partition from the system and be adsorbed by the mucosa giving faster onset of action and greater symptom relief.
  • the spray compositions may also include conventional additives such as essential oils, fragrances, flavors, sweeteners, menthol, pepperment oil, pine tar, camphor, benzoin preparations, tolu, turpentine oil and the like.
  • the carrier is a cyclopentasiloxane, preferably a polyalkylcyclopentasiloxxane an ethylene diglyceride, a propylene glyceride, and mixtures of said glycerides. It especially desirable that the carrier is decamethylcyclopentasiloxane, an ethylene diglyceride, a propylene diglyceride, a propylene triglyceride and mixtures of said glycerides, wherein the glyceride moieties are selected from the group consisting of caprilic and capric glycerides.
  • the ester is a lactate ester, desirably it is a C 12 to C 18 alkyl lactate, preferably where the alkyl group is cetyl, lauryl, isostearyl and myristyl and mixtures thereof.
  • the glycol is a C 3 to C 8 glycol, including but not limited to propylene, dipropylene, hexylene, 1,3-butylene, diethylene, triethylene, tetrapropylene and tetraethylene glycols, polyethylene glycol 200 and polypropylene glycol 425 amd 2-methyl-1,3-propane diol and mixtures thereof
  • bio-active materials suitable for use in this invention include those selected from the group consisting of decongestants, antihistamines, analgesics such as butorphanol tartrateantitussives, anticholinergics, steroids, suitably corticosteroids such as triamcinolone acetonide antibiotics antispasmotics, such as beclamethasone dipropionate, brochodilators, such as ipratropium bromide, fluticasone pripionate, albuterol sulfate, vitamins, such as vitamine B-12 or cyanocobalamine, hormones, suitably peptide hormones such as calcitonin-salmon, antihypertensives such as propranolol, and antimicrobials.
  • decongestants such as decongestants, antihistamines, analgesics such as butorphanol tartrateantitussives, anticholinergics, steroids, suitably corticosteroids such as triam
  • bio-active material Especially suitable for purposes of this invention as the bio-active material are decongestants.
  • decongestants Most suitably oxymetazoline, xylometazoline, naphazoline, phenylephrine, ephedrine in water soluble form especially when in the form of a pharmacologically acceptable salt, such as a hydrochloride or sulfate.
  • the ranges of the components of the spray composition are suitably from about 50-about 90 wt. % of the carrier, from about 10-about 40 wt % of the water insoluble ester, from about 1 to about 5 wt. % of the water soluble glycol, and from about 0.01 to about 2 wt. % of the bio-active material, to a total wt % of 100.
  • the ranges are from about 60 about 90 wt. % of the carrier, from about 10 about 30 wt % of the water insoluble ester, from about 1 to about 3 wt. % of the water soluble glycol and from about 0.01 to about 2 wt. % of the bio-active material.
  • the sprays of the present invention are administered by spraying into the nasal cavity.
  • the actual volume sprayed may lie between about 20 and about 80 micro liters. This amount is readily set by those skilled in the art of valve design for squeeze bottles and spray bottles.
  • the dosage of bio-active delivered is determined by its concentration in the composition.
  • the needed frequency of administration may be readily determined by those skilled in the art based on present knowledge and not requiring undue experimentation.
  • Components # 1 and #2 are heated to 50° C. until clear and uniform then the batch is cooled the #3 is added with mixing and when clear, #4 is added and mixed. The batch may then be charged to a spray container in suitable quantities.
  • Components # 1, #2 and #3 are heated to 50° C. until clear and uniform then the batch is cooled the #4 is added with mixing and when clear, #5 is added and mixed. The batch may then be charged to a spray container in suitable quantities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is provided non-aqueous liquid spray compositions comprising a pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble, a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier, a pharmacologically acceptable water soluble glycol soluble in said ester and a pharmacologically acceptable water soluble bio-active material soluble in said glycol but not directly soluble in the carrier. There are also provided methods of producing and administering such compositions.

Description

    RELATED APPLICATIONS
  • This application is a continuation in part of applicants copending application Ser. No. 10/253,073, filed Sep. 23, 2002.[0001]
    • FIELD OF THE INVENTION
  • Safe, non irritating, non aqueous spray compositions administrable via the nasal cavity. [0002]
    • BACKGROUND OF THE INVENTION DISCUSSION OF THE PRIOR ART
  • The use of nasal sprays to provide relief from the nasal stuffiness of colds and allergic rhinitis is widespread. Various sympathomimetic amines have been used to provide relief. Nasal decongestants stimulate the alpha-adrenergic receptors of the vascular smooth muscle. This constriction results in shrinkage of the engorged mucous membranes which promotes drainage; improves nasal ventilation and relieves the feeling of stuffiness. [0003]
  • Many decongestants are commercially available and are used to give various lengths of relief from 4 hours up to 12 hours. All of these decongestants are water soluble and are delivered in aqueous spray Systems. [0004]
  • The decongestant solutions are delivered by spray from either a flexible plastic container that produces a mist when squeezed or by a hand operated mechanical pump. [0005]
  • These aqueous sprays are wet, cold and drip from the nose. They are very uncomfortable to use. Since they are aqueous based and the nozzle is inserted in the nostril, bacterial contamination of the product easily occurs. Nasal sprays are difficult to preserve. [0006]
  • The mucous layer lining the epithelium represents a barrier to drug absorption along with mucociliary clearance mechanisms of the nose leads to short residence time of aqueous systems at the site of absorption which limits the systemic availability of the drug. [0007]
    • SUMMARY OF THE INVENTION
  • The invention is directed to compositions of incorporating an effective dosage of decongestant or other drug from a safe, non-aqueous, non-irritating, tastless and odorless liquid carrier system that delivers an extremely fine, non-dripping, warm, pleasant spray to the nasal cavity from either a squeeze bottle or pump spray system. [0008]
  • There is provided a non-aqueous liquid spray composition for a bioactive material comprising a pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble, a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier, a pharmacologically acceptable water soluble glycol soluble in said ester, a pharmacologically acceptable water soluble bio-active material soluble in said glycol but directly insoluble, that is to say cannot be directly dissolved in in said carrier. [0009]
  • The spray compositions of the present invention are produced by the sequential steps of dissolving the bio-active material in a glycol, dissolving the resultant solution in a water insoluble ester of a water soluble acid and dissolving said further resultant solution in a suitable carrier as discussed above. [0010]
  • The spray compositions of the present invention containing the appropriate bio-active material may be administered to a subject in need of same by spraying a pharmacologically effective amount of such a composition into the nasal cavity of said subject. This may be done using any spray method, such as using a pump spray device or a squeeze bottle spray, the latter being inexpensive and especially suitable. [0011]
  • The system of the present invention possesses several advantages over the aqueous nasal administration systems heretofore available. It provides a fine, warm, dripless, non-irritating spray, which, depending on the drug used, gives 4-12 hour decongestant relief. Because the system is non-aqueous, no preservatives are needed and the system will resist recontamination. [0012]
  • Furthermore because the system is anhydrous, it will wet out and cling to the mucous membrane of the nasal passages. Being water resistant, it will resist removal by the mucocillary clearance mechanism; thereby allowing more contact time at the site. The drugs will partition from the system and be adsorbed by the mucosa giving faster onset of action and greater symptom relief. [0013]
  • The system works exceptionally well with all commercially available spray systems. In fact, the efficacy of squeeze bottle system is comparable to the more expensive pump spray delivery. [0014]
  • All ingredients are safe for use in the nose. The esters and glycols used manifest a moisturizing effect which will keep the nasal tissues soft and supple thereby eliminating nasal dryness. In addition to the bio-active materials to be administered, the spray compositions may also include conventional additives such as essential oils, fragrances, flavors, sweeteners, menthol, pepperment oil, pine tar, camphor, benzoin preparations, tolu, turpentine oil and the like. [0015]
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Suitably the carrier is a cyclopentasiloxane, preferably a polyalkylcyclopentasiloxxane an ethylene diglyceride, a propylene glyceride, and mixtures of said glycerides. It especially desirable that the carrier is decamethylcyclopentasiloxane, an ethylene diglyceride, a propylene diglyceride, a propylene triglyceride and mixtures of said glycerides, wherein the glyceride moieties are selected from the group consisting of caprilic and capric glycerides. [0016]
  • Suitably the ester is a lactate ester, desirably it is a C[0017] 12 to C18 alkyl lactate, preferably where the alkyl group is cetyl, lauryl, isostearyl and myristyl and mixtures thereof.
  • Preferably, the glycol is a C[0018] 3 to C8 glycol, including but not limited to propylene, dipropylene, hexylene, 1,3-butylene, diethylene, triethylene, tetrapropylene and tetraethylene glycols, polyethylene glycol 200 and polypropylene glycol 425 amd 2-methyl-1,3-propane diol and mixtures thereof
  • While the invention is not limited thereto, bio-active materials suitable for use in this invention include those selected from the group consisting of decongestants, antihistamines, analgesics such as butorphanol tartrateantitussives, anticholinergics, steroids, suitably corticosteroids such as triamcinolone acetonide antibiotics antispasmotics, such as beclamethasone dipropionate, brochodilators, such as ipratropium bromide, fluticasone pripionate, albuterol sulfate, vitamins, such as vitamine B-12 or cyanocobalamine, hormones, suitably peptide hormones such as calcitonin-salmon, antihypertensives such as propranolol, and antimicrobials. [0019]
  • Especially suitable for purposes of this invention as the bio-active material are decongestants. Most suitably oxymetazoline, xylometazoline, naphazoline, phenylephrine, ephedrine in water soluble form especially when in the form of a pharmacologically acceptable salt, such as a hydrochloride or sulfate. [0020]
  • The ranges of the components of the spray composition are suitably from about 50-about 90 wt. % of the carrier, from about 10-about 40 wt % of the water insoluble ester, from about 1 to about 5 wt. % of the water soluble glycol, and from about 0.01 to about 2 wt. % of the bio-active material, to a total wt % of 100. Preferably the ranges are from about 60 about 90 wt. % of the carrier, from about 10 about 30 wt % of the water insoluble ester, from about 1 to about 3 wt. % of the water soluble glycol and from about 0.01 to about 2 wt. % of the bio-active material. [0021]
  • The sprays of the present invention are administered by spraying into the nasal cavity. The actual volume sprayed may lie between about 20 and about 80 micro liters. This amount is readily set by those skilled in the art of valve design for squeeze bottles and spray bottles. Thus the dosage of bio-active delivered is determined by its concentration in the composition. The needed frequency of administration may be readily determined by those skilled in the art based on present knowledge and not requiring undue experimentation. [0022]
    • EXAMPLES
  • (All quantities are in wt. % unless otherwise noted) [0023]
    • Example #1 Nasal Decongestant 12 Hour Duration
  • [0024]
    1. Oxymetazoline.HCl 0.05
    2. Propylene Glycol 2.50
    3. C12—C15 Alkyl Lactate 20.00
    4. Dimethylcyclopentasiloxane 77.45
    100.00
  • Components # 1 and #2 are heated to 50° C. until clear and uniform then the batch is cooled the #3 is added with mixing and when clear, #4 is added and mixed. The batch may then be charged to a spray container in suitable quantities. [0025]
    • Example #2 Nasal Decongestant 8 Hour Duration
  • [0026]
    1. Xylometazoline.HCl 0.10
    2. Propylene Glycol 2.50
    3. C12—C15 Alkyl Lactate 20.00
    4. Cyclopentasiloxane 77.40
    100.00
  • This mixture is prepared in accordance with the procedures of Example #1 [0027]
    • Example #3 Nasal Decongestant 4 Hour Duration
  • [0028]
    1. Phenylephrine.HCl 0.50
    2. Propylene Glycol 5.00
    3. C12—C15 Alkyl Lactate 30.00
    4. Cyclopentasiloxane 64.50
    100.00
  • This mixture is prepared in accordance with the procedures of Example #1 [0029]
    • Example #4 Nasal Decongestant 12 Hour Duration
  • [0030]
    1. Oxymetazoline.HCl 0.05
    2. 1,3-Butylene Glycol 2.50
    3. Lauryl Lactate 20.00
    4. Cyclopentasiloxane 77.45
    100.00
  • This mixture is prepared in accordance with the procedures of Example #1 [0031]
    • Example #5 Nasal Decongestant and Antihistamine
  • [0032]
    1. Oxymetazoline.HCl 0.05
    2. Chlorpheniramine Maleate 0.20
    3. Propylene Glycol 2.50
    4. Myristyl Lactate 20.00
    5. Cyclopentasiloxane 77.25
    100.00
  • Components # 1, #2 and #3 are heated to 50° C. until clear and uniform then the batch is cooled the #4 is added with mixing and when clear, #5 is added and mixed. The batch may then be charged to a spray container in suitable quantities. [0033]
    • Example #6 Nasal Decongestant
  • [0034]
    1. Oxymetazoline.HCl 0.05
    2. Propylene Glycol 2.00
    3. Isostearyl Lactate 23.00
    4. Cyclopentasiloxane 74.95
    100.00
  • This mixture is prepared in accordance with the procedures of Example #1 [0035]
    • Example #7 Nasal Decongestant 12 Hour Duration
  • [0036]
    1. Oxymetazoline HCl  0.05%
    2. Propylene Glycol  1.50%
    3. C12—C15 Alkyl Lactate  20.00%
    4. Caprylic/Capric Triglyceride  78.45%
    100.00%
  • This mixture is prepared in accordance with the procedures of Example #1. [0037]
    • Example #8 12 Hour Duration Nasal Decongestant
  • [0038]
    1. Oxymetazoline HCl  0.05%
    2. Propylene Glycol  1.50%
    3. C12—C15 Alkyl Lactate  10.00%
    4. Propylene Glycol Dicaprylate/Dicaprate  88.45%
    100.00%
  • This mixture is prepared in accordance with the procedures of Example #1. [0039]

Claims (23)

1. A non-aqueous liquid spray composition for a bioactive material comprising
1) a pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble,
b) a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier,
c) a pharmacologically acceptable water soluble glycol soluble in said ester,
d) a pharmacologically acceptable water soluble bio-active material soluble in said glycol but directly insoluble in said carrier.
2. The composition of claim 1 wherein . the carrier is selected from the group consisting of a cyclopentasiloxane, an ethylene diglyceride, a propylene diglyceride, a propylene triglyceride and mixtures of said glycerides.
3. The composition of claim 2 wherein the cyclopentasiloxane is a polyalkylcyclopentasiloxane.
4. The composition of claim 3 wherein the carrier is selected from the group consisting of decamethylcyclopentylsiloxane, an ethylene diglyceride, a propylene diglyceride, a propylene triglyceride and mixtures of said glycerides, wherein the glyceride moieties are selected from the group consisting of cAprilic and capric glycerides.
5. The composition of claim 1 comprising
a) from about 50-about 90 wt. % of the carrier,
b) from about 1 0-about 40 wt % of the water insoluble ester,
c) from about 1-about 5 wt. % of the water soluble glycol,
d) from about 0-01-about 2 wt. % of the bio-active material.
6. The composition of claim 1 comprising
a) from about 60 about 90 wt. % of the carrier,
b) from about 10 about 20 wt % of the water insoluble ester,
c) from about 1 to about 3 wt. % of the water soluble glycol,
d) from about 0.01 to about 2 wt. % of the bio-active material.
7. The composition of claim 5 wherein the glycol is a C3 to C8 glycol.
8. The composition of claim 7 wherein the glycol is selected from the group consisting of polyethylene glycol and polypropylene glycol.
9. The composition of claim 5 wherein the ester is a lactate ester.
10. The composition of claim 9 wherein the lactate ester is a C12- C15 alkyl lactate
11. The composition of claim 10 wherein the alkyl group is selected from the group consisting of cetyl, lauryl, isostearyl and myristyl and mixtures thereof
12. The composition of claim 5 wherein the bio-active material is selected from the group consisting of decongestants, antihistamines, antitussives, anticholinergics, steroids, antibiotics, analgesics, antispasmotics, brocho-dilators, vitamins, hormones, antihypertensives and antimicrobials.
13. The composition of claim 5 wherein the bio-active material is a decongestant.
14. The composition of claim 13 wherein the bio-active material is selected from the group consisting of oxymetazoline, xylometazoline, naphazoline, phenylephrine, ephedrine in water soluble form.
15. The composition of claim 14 wherein the bio-active material is in the form of a pharmacologically acceptable salt.
16. The composition of claim 15 wherein the salt is a hydrochloride or sulfate.
17. A method of producing a spray composition of claim 1 which comprises the sequential steps of dissolving the bio-active material of (d) in a glycol of (c), dissolving said solution of (d) in (c) in an ester of (b) and dissolving said solution of (d) in (c)) in (b) in a carrier of (a).
18. The method of producing a spray composition of claim 2 which comprises the sequential steps of dissolving the bio-active material of (d) in a glycol of (c), dissolving said solution of (d) in (c) in an ester of (b) and dissolving said solution of (d) in(c) ) in (b) in a carrier (a) as defined in claim 2.
19. The method of producing a spray composition of claim 5 which comprises the sequential steps of dissolving the bio-active material of (d) in a glycol of (c), dissolving said solution of (d) in (c) in an ester of (b) and dissolving said solution of (d) in (c) in (b) in a carrier of (a) selected from the group consisting of decamethylcyclopentylsiloxane, an ethylene diglyceride, a propylene diglyceride, a propylene triglyceride and mixtures of said glycerides, wherein the glyceride moieties are selected from the group consisting of cAprilic and capric glycerides.
20. A method of administering a bio-active material to a subject in need of same which comprises spraying a pharmacologically effective amount of a composition of claim 1 into the nasal cavity of said subject.
21. The method of claim 20, wherein the bio-active material is selected from the group consisting of decongestants, antihistamines, antitussives, anticholinergics, steroids, analgesics antibiotics, antispasmotics, brochodilators, vitamins, hormones, antihypertensives and antimicrobials.
22. The method of claim 21, wherein the bio-active material is a decongestant.
23. The method of claim 22, wherein the bio-active material is selected from the group consisting of oxymetazoline, xylometazoline, naphazoline, phenylephrine, ephedrine in water soluble form.
US10/406,869 2002-09-23 2003-04-04 Dri-nasal sprays Abandoned US20040057907A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/406,869 US20040057907A1 (en) 2002-09-23 2003-04-04 Dri-nasal sprays
US10/526,386 US7332528B2 (en) 2002-09-23 2003-09-10 DRI nasal sprays
PCT/US2003/028272 WO2004026362A2 (en) 2002-09-23 2003-09-10 Dri nasal sprays
CA002499900A CA2499900A1 (en) 2002-09-23 2003-09-10 Dri nasal sprays
AU2003272306A AU2003272306A1 (en) 2002-09-23 2003-09-10 Dri nasal sprays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25307302A 2002-09-23 2002-09-23
US10/406,869 US20040057907A1 (en) 2002-09-23 2003-04-04 Dri-nasal sprays

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US25307302A Continuation-In-Part 2002-09-23 2002-09-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/526,386 Continuation US7332528B2 (en) 2002-09-23 2003-09-10 DRI nasal sprays

Publications (1)

Publication Number Publication Date
US20040057907A1 true US20040057907A1 (en) 2004-03-25

Family

ID=36752883

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/406,869 Abandoned US20040057907A1 (en) 2002-09-23 2003-04-04 Dri-nasal sprays
US10/526,386 Expired - Fee Related US7332528B2 (en) 2002-09-23 2003-09-10 DRI nasal sprays

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/526,386 Expired - Fee Related US7332528B2 (en) 2002-09-23 2003-09-10 DRI nasal sprays

Country Status (4)

Country Link
US (2) US20040057907A1 (en)
AU (1) AU2003272306A1 (en)
CA (1) CA2499900A1 (en)
WO (1) WO2004026362A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
CN101137357B (en) * 2005-03-10 2012-07-04 3M创新有限公司 Antimicrobial compositions comprising esters of hydroxycarboxylic acids
US20170196783A1 (en) * 2016-01-13 2017-07-13 Jehangir Gowani Pharyngeal or buccal cavity rinse and process of use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100213313A1 (en) * 2006-11-06 2010-08-26 Goodrich Corporation Integrated aircraft cargo loading and cargo video monitoring system
US8515656B2 (en) * 2007-11-02 2013-08-20 Goodrich Corporation Integrated aircraft cargo loading and monitoring system
CN104260896B (en) * 2014-09-01 2017-01-11 陈宜中 Method for passengers to participate in alarming when passenger plane meets with hijacking

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US5854269A (en) * 1993-11-19 1998-12-29 Schering-Plough Healthcare Products, Inc. Nasal spray compositions
US6391294B1 (en) * 1997-08-21 2002-05-21 Reckitt Benckiser Healthcare (Uk) Limited In situ formation of polymeric material

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832945A (en) * 1986-05-28 1989-05-23 Osipow Lloyd I Deodorant stick
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
JPH0776526A (en) * 1993-09-06 1995-03-20 Sansei Seiyaku Kk Transcutaneous absorption preparation containing lactic acid ester
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
FR2740038B1 (en) * 1995-10-20 1998-01-02 Lafon Labor COMPOSITION FOR TRANSDERMAL ADMINISTRATION
ES2191834T3 (en) * 1996-10-24 2003-09-16 Alza Corp AGENTS THAT FACILITATE THE PERMEATION AND DESTINATIONS FOR COMPOSITIONS, DEVICES AND PROCEDURES OF TRANSDERMAL CONTRIBUTION OF DRUGS.
EP1001747A1 (en) * 1997-08-09 2000-05-24 Smithkline Beecham Plc Compositions for nasal administration
DE19925289A1 (en) * 1999-06-02 2000-12-07 Hexal Ag Stable, well-tolerated composition for intranasal administration of water-soluble drugs, e.g. nicotine, comprising drug, neutral oil (preferably triglyceride) and optionally solubilizer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US5854269A (en) * 1993-11-19 1998-12-29 Schering-Plough Healthcare Products, Inc. Nasal spray compositions
US6391294B1 (en) * 1997-08-21 2002-05-21 Reckitt Benckiser Healthcare (Uk) Limited In situ formation of polymeric material

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137357B (en) * 2005-03-10 2012-07-04 3M创新有限公司 Antimicrobial compositions comprising esters of hydroxycarboxylic acids
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20170196783A1 (en) * 2016-01-13 2017-07-13 Jehangir Gowani Pharyngeal or buccal cavity rinse and process of use thereof
US10434119B2 (en) * 2016-01-13 2019-10-08 Gargle Water, Inc. Pharyngeal or buccal cavity rinse and process of use thereof

Also Published As

Publication number Publication date
CA2499900A1 (en) 2004-04-01
WO2004026362A2 (en) 2004-04-01
US20060024237A1 (en) 2006-02-02
US7332528B2 (en) 2008-02-19
AU2003272306A8 (en) 2004-04-08
WO2004026362A3 (en) 2004-09-16
AU2003272306A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
US6375984B1 (en) Aqueous-based pharmaceutical composition
US5981591A (en) Sprayable analgesic composition and method of use
EP1296650B1 (en) Methods and compositions for treating pain of the mucous membrane
DK2613793T3 (en) NOSE SPRAY
US20030190290A1 (en) Pharmaceutical compositions
US20090286867A1 (en) Compositions and methods of administering doxepin to mucosal tissue
AU6878098A (en) Topical nasal antiinflammatory compositions
EP0627915B1 (en) Sprayable analgesic composition and method of use
US7332528B2 (en) DRI nasal sprays
MXPA06009094A (en) Controlled release formulations.
US11951077B2 (en) Stabilized menthol and other volatile compound compositions and methods
JP2001089359A (en) Gel or gel preparation for nasal drip of analgesic component
JP2003081812A (en) Aerosol preparation
JP3350678B2 (en) Oral aerosol products
JP2005187404A (en) External spray composition for mucosa, nasal drop and preparation for oral cavity/throat disease
JPH0925244A (en) Antiphlogistic and analgesic composition
EP1559418A1 (en) Compositions for treating pain of the mucous membrane
AU2003263416B2 (en) Pharmaceutical compositions for buccal delivery of pain relief medications

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION